The Scientific Basis of Heart Failure in the Young

描述（由申请人提供）： 年轻人心力衰竭（HF）是一种常见的临床疾病，具有显著的发病率和死亡率，并带来长期的社会和经济成本。主要原因是先天性心脏病，这是最常见的出生缺陷，发病率近1%。它也是潜在寿命损失的第五大原因，每1000人中有2人。在美国，超过45万儿童和超过100万成年人患有先天性心脏病，强调其对公共卫生的影响。此外，遗传性心肌病和获得性心脏病，如心肌炎，也是年轻人HF的总体负担。尽管HF在年轻人、儿童和婴儿中很重要，但与丰富的文献和对成人HF的基本了解相比，对其研究较少。因此，HF儿童的治疗进展缓慢。事实上，当今儿童HF管理的大多数新概念都是基于成人治疗策略的翻译，很少有临床前证据支持其在年轻人中的使用。然而，最近在心脏形态发生的分子调控以及心脏对损伤的细胞和分子反应方面令人兴奋的发现，为了解年轻人的HF提供了新的工具。这个为期3天的会议的目的是介绍目前的临床和基础研究的基础上，在儿童心力衰竭，并制定了未来的方向，在心力衰竭研究，为这一服务不足的人口。会议将保持相对较小的规模（约150名与会者），以保持与会者之间的高质量互动，并继续关注儿童HF的科学基础。会议地点选在科罗拉多的埃斯蒂斯公园，是为了在非正式场合加强这些互动，会议定于2007年秋季举行。在为期2.5天的会议中，将提出五个广泛的研究领域：1）年轻人HF的基本机制。2)用于定量HF的基本和新颖工具。3)心力衰竭的新型疗法。4)年轻人HF的临床科学。5）。成人先天性心脏病。本次会议有4个目标：1）增加对年轻人HF临床和基础研究的关注。2)加强基础和临床研究人员之间的合作，重点关注年轻人的HF。3)提高对儿童和年轻人HF基础及其治疗的临床理解。4)增加对新概念和新想法的理解，以了解HF及其在年轻人中的治疗。考虑到年轻人HF的不同病因，我们对指导心脏胚胎学和收缩功能的基因程序的快速了解，以及手术后存活的儿童人群的快速增长，这些儿童现在具有迟发HF的高风险，迫切需要了解年轻人的HF，以便设计新的治疗策略并合理应用当前的治疗方法。

DESCRIPTION (provided by applicant): Heart failure (HF) in the young is a common clinical entity that has significant morbidity and mortality and carries substantial long-term social and financial costs. The leading cause is congenital heart disease, which is the most common birth defect with an incidence of almost 1%. It is also the 5th ranked cause of years of potential life lost at 2 per 1000 population. Well over 450,000 children and over 1 million adults in the USA have a congenital heart defect emphasizing its impact on public health. In addition, inherited cardiomyopathies, and acquired heart disease, such as myocarditis, contribute to the overall burden of HF in the young. Despite the importance of HF in young adults, children and infants, it has been less well studied when compared with the rich literature and basic understanding of HF in adults. As a result, therapy for children with HF has advanced more slowly. Indeed, most new concepts for management of HF in children today are based on translation of adult treatment strategies with little preclinical evidence supporting their use in the young. However, recent and exciting discoveries in the molecular regulation of cardiac morphogenesis, as well as in the cellular and molecular response of the heart to injury, have provided new tools to understand HF in the young. The goal of this 3 day conference is to present current clinical and basic research on the basis of HF in children, and map out future directions in heart failure research for this underserved population. The conference will be kept relatively small (~150 participants) in order to maintain a high quality of interaction between participants, and to remain focused on the scientific basis of HF in children. The venue for this meeting, Estes Park, Colorado, is chosen to enhance these interactions in an informal setting, and is planned for the Fall of 2007. Five broad areas of research will be presented across the 2.5 days of the meeting: 1) Basic mechanisms of HF in the young. 2) Basic and novel tools for quantifying HF. 3) Novel therapies for HF. 4) Clinical science of HF in the young. 5). Adult congenital heart disease. This conference has 4 goals: 1) Increased attention to the need for clinical and basic research on HF in the young. 2) Increased collaborations between basic and clinical researchers to focus on HF in the young. 3) Improved clinical understanding of the basis for HF and its treatment in children and young adults. 4) Increased understanding of novel concepts and new ideas for understanding HF and it's treatment in the young. Given the different etiologies of HF in the young, our rapidly advancing knowledge of gene programs directing cardiac embryology and contractile function, and the rapidly growing population of children surviving surgery who now have a high risk of late onset HF, there is an urgent need to understand HF in the young in order to design new treatment strategies and rationally apply current therapies.